Carcinoma, Bronchogenic  >>  Erbitux (cetuximab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
NCT00207116: An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Completed
1
120
US
Cetuximab, Erbitux
Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
03/06
03/06
NCT00162318: A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Completed
1
30
US
Cetuximab + Gefitinib, Erbitux
Eli Lilly and Company
Non-Small-Cell Lung Carcinoma
04/06
04/06
NCT00522886: Phase I Cetuximab and Concurrent Radio-chemotherapy

Completed
1
24
Europe
Cetuximab
Maastricht Radiation Oncology, Academisch Ziekenhuis Maastricht, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/11
 
NCT01090011 / 2009-015911-42: Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Completed
1
171
US, Europe
Cetuximab, BIBW 2992
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
01/13
08/14
NCT01451632: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1
48
US
MM-121, Seribantumab, SAR256212, Irinotecan, Camptosar, Cetuximab, Erbitux
Merrimack Pharmaceuticals, Sanofi
Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence
11/13
06/14

Download Options